Skip to main content
Erschienen in: Heart and Vessels 10/2016

21.01.2016 | Case Report

Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24–32

verfasst von: Jun Maeda, Kenjiro Kosaki, Junko Shiono, Kazuki Kouno, Ryo Aeba, Hiroyuki Yamagishi

Erschienen in: Heart and Vessels | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

A subgroup of patients with Marfan syndrome (MFS) who have mutations in exons 24–32 of the FBN1 gene manifests severe atrioventricular valve insufficiency and skeletal problems as early as the neonatal period. These patients usually die in the first 2 years of life, thus a region between exons 24 and 32 of FBN1 is recognized as a critical region for this neonatal form of MFS (nMFS). Here, we report five consecutive patients who manifested a cardiovascular phenotype until infancy with mutations in the critical region for nMFS. Although three of these patients showed severe mitral regurgitation and died before reaching 1 year of age, the remaining two patients survived for over 5 years under medical and/or surgical interventions. Two splicing mutations and one missense mutation were identified in the three deceased patients, whereas two missense mutations were found in the two survivors. Currently, the clinical severity of patients with early-onset MFS harboring mutations in the critical region for nMFS seem to be more variable than ever thought, and intensive treatments are recommended even in this subgroup of patients with MFS.
Literatur
1.
Zurück zum Zitat Hennekam RC (2005) Severe infantile Marfan syndrome versus neonatal Marfan syndrome. Am J Med Genet A 139:1CrossRefPubMed Hennekam RC (2005) Severe infantile Marfan syndrome versus neonatal Marfan syndrome. Am J Med Genet A 139:1CrossRefPubMed
2.
Zurück zum Zitat Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Matyas G, Nuytinck L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C (2003) Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 22:199–208CrossRefPubMed Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Matyas G, Nuytinck L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C (2003) Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 22:199–208CrossRefPubMed
3.
Zurück zum Zitat Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM (1996) Delineation of the Marfan phenotype associated with mutations in exons 23–32 of the FBN1 gene. Am J Med Genet 62:233–242CrossRefPubMed Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM (1996) Delineation of the Marfan phenotype associated with mutations in exons 23–32 of the FBN1 gene. Am J Med Genet 62:233–242CrossRefPubMed
4.
Zurück zum Zitat Faivre L, Collod-Beroud G, Callewaert B, Child A, Binquet C, Gautier E, Loeys BL, Arbustini E, Mayer K, Arslan-Kirchner M, Stheneur C, Kiotsekoglou A, Comeglio P, Marziliano N, Wolf JE, Bouchot O, Khau-Van-Kien P, Beroud C, Claustres M, Bonithon-Kopp C, Robinson PN, Adès L, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C (2009) Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24–32 mutation. Eur J Hum Genet 17:491–501CrossRefPubMed Faivre L, Collod-Beroud G, Callewaert B, Child A, Binquet C, Gautier E, Loeys BL, Arbustini E, Mayer K, Arslan-Kirchner M, Stheneur C, Kiotsekoglou A, Comeglio P, Marziliano N, Wolf JE, Bouchot O, Khau-Van-Kien P, Beroud C, Claustres M, Bonithon-Kopp C, Robinson PN, Adès L, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C (2009) Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24–32 mutation. Eur J Hum Genet 17:491–501CrossRefPubMed
5.
Zurück zum Zitat Stheneur C, Faivre L, Collod-Béroud G, Gautier E, Binquet C, Bonithon-Kopp C, Claustres M, Child AH, Arbustini E, Adès LC, Francke U, Mayer K, Arslan-Kirchner M, De Paepe A, Chevallier B, Bonnet D, Jondeau G, Boileau C (2011) Prognosis factors in probands with an FBN1 mutation diagnosed before the age of 1 year. Pediatr Res 69:265–270CrossRefPubMed Stheneur C, Faivre L, Collod-Béroud G, Gautier E, Binquet C, Bonithon-Kopp C, Claustres M, Child AH, Arbustini E, Adès LC, Francke U, Mayer K, Arslan-Kirchner M, De Paepe A, Chevallier B, Bonnet D, Jondeau G, Boileau C (2011) Prognosis factors in probands with an FBN1 mutation diagnosed before the age of 1 year. Pediatr Res 69:265–270CrossRefPubMed
6.
Zurück zum Zitat Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47:476–485CrossRefPubMed Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47:476–485CrossRefPubMed
7.
Zurück zum Zitat Pettersen MD, Du W, Skeens ME, Humes RA (2008) Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 21:922–934CrossRefPubMed Pettersen MD, Du W, Skeens ME, Humes RA (2008) Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 21:922–934CrossRefPubMed
8.
Zurück zum Zitat Booms P, Cisler J, Mathews KR, Godfrey M, Tiecke F, Kaufmann UC, Vetter U, Hagemeier C, Robinson PN (1999) Novel exon skipping mutation in the fibrillin-1 gene: two ‘hot spots’ for the neonatal Marfan syndrome. Clin Genet 55:110–117CrossRefPubMed Booms P, Cisler J, Mathews KR, Godfrey M, Tiecke F, Kaufmann UC, Vetter U, Hagemeier C, Robinson PN (1999) Novel exon skipping mutation in the fibrillin-1 gene: two ‘hot spots’ for the neonatal Marfan syndrome. Clin Genet 55:110–117CrossRefPubMed
9.
Zurück zum Zitat Liu W, Qian C, Comeau K, Brenn T, Furthmayr H, Francke U (1996) Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe Marfan syndrome. Hum Mol Genet 5:1581–1587CrossRefPubMed Liu W, Qian C, Comeau K, Brenn T, Furthmayr H, Francke U (1996) Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe Marfan syndrome. Hum Mol Genet 5:1581–1587CrossRefPubMed
10.
Zurück zum Zitat Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, Mathews KR, Scheuner M, Hinkel GK, Brenner RE, Hövels-Gürich HH, Hagemeier C, Fuchs J, Skovby F, Rosenberg T (2001) Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24–40. Eur J Hum Genet 9:13–21CrossRefPubMed Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, Mathews KR, Scheuner M, Hinkel GK, Brenner RE, Hövels-Gürich HH, Hagemeier C, Fuchs J, Skovby F, Rosenberg T (2001) Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24–40. Eur J Hum Genet 9:13–21CrossRefPubMed
11.
Zurück zum Zitat Barnett CP, Wilson GJ, Chiasson DA, Gross GJ, Hinek A, Hawkins C, Chitayat D (2010) Central nervous system abnormalities in two cases with neonatal Marfan syndrome with novel mutations in the fibrillin-1 gene. Am J Med Genet A 152A:2409–2412CrossRefPubMed Barnett CP, Wilson GJ, Chiasson DA, Gross GJ, Hinek A, Hawkins C, Chitayat D (2010) Central nervous system abnormalities in two cases with neonatal Marfan syndrome with novel mutations in the fibrillin-1 gene. Am J Med Genet A 152A:2409–2412CrossRefPubMed
12.
Zurück zum Zitat Giusti B, Porciani MC, Brunelli T, Evangelisti L, Fedi S, Gensini GF, Abbate R, Sani G, Yacoub M, Pepe G (2003) Phenotypic variability of cardiovascular manifestations in Marfan syndrome. possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J 24:2038–2045CrossRefPubMed Giusti B, Porciani MC, Brunelli T, Evangelisti L, Fedi S, Gensini GF, Abbate R, Sani G, Yacoub M, Pepe G (2003) Phenotypic variability of cardiovascular manifestations in Marfan syndrome. possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J 24:2038–2045CrossRefPubMed
13.
Zurück zum Zitat Attanasio M, Lapini I, Evangelisti L, Lucarini L, Giusti B, Porciani M, Fattori R, Anichini C, Abbate R, Gensini G, Pepe G (2008) FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations. Clin Genet 74:39–46CrossRefPubMed Attanasio M, Lapini I, Evangelisti L, Lucarini L, Giusti B, Porciani M, Fattori R, Anichini C, Abbate R, Gensini G, Pepe G (2008) FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations. Clin Genet 74:39–46CrossRefPubMed
14.
Zurück zum Zitat Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, Ramirez F, Pyeritz RE, Dietz HC (1995) Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 57:8–21PubMedPubMedCentral Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, Ramirez F, Pyeritz RE, Dietz HC (1995) Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 57:8–21PubMedPubMedCentral
15.
Zurück zum Zitat Summers KM, Nataatmadja M, Xu D, West MJ, McGill JJ, Whight C, Colley A, Adès LC (2005) Histopathology and fibrillin-1 distribution in severe early onset Marfan syndrome. Am J Med Genet A 139:2–8CrossRefPubMed Summers KM, Nataatmadja M, Xu D, West MJ, McGill JJ, Whight C, Colley A, Adès LC (2005) Histopathology and fibrillin-1 distribution in severe early onset Marfan syndrome. Am J Med Genet A 139:2–8CrossRefPubMed
16.
Zurück zum Zitat Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A (2001) Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 161:2447–2454CrossRefPubMed Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A (2001) Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 161:2447–2454CrossRefPubMed
17.
Zurück zum Zitat Wang M, Wang J-Y, Cisler J, Imaizumi K, Burton BK, Jones MC, Lamberti JL, Godfrey M (1997) Three novel fibrillin mutations in exons 25 and 27: classic versus neonatal Marfan syndrome. Hum Mutat 9:359–362CrossRefPubMed Wang M, Wang J-Y, Cisler J, Imaizumi K, Burton BK, Jones MC, Lamberti JL, Godfrey M (1997) Three novel fibrillin mutations in exons 25 and 27: classic versus neonatal Marfan syndrome. Hum Mutat 9:359–362CrossRefPubMed
18.
Zurück zum Zitat Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U (1999) Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet 65:1007–1020CrossRefPubMedPubMedCentral Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U (1999) Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet 65:1007–1020CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Adès LC, Haan EA, Colley AF, Richard RI (1996) Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome. J Med Genet 33:665–671CrossRefPubMedPubMedCentral Adès LC, Haan EA, Colley AF, Richard RI (1996) Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome. J Med Genet 33:665–671CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Pepe G, Giusti B, Attanasio M, Comeglio P, Porciani MC, Giurlani L, Montesi GF, Calamai GC, Vaccari M, Favilli S, Abbate R, Gensini GF (1997) A major involvement of the cardiovascular system in patients affected by Marfan syndrome: novel mutations in fibrillin 1 gene. J Mol Cell Cardiol 29:1877–1884CrossRefPubMed Pepe G, Giusti B, Attanasio M, Comeglio P, Porciani MC, Giurlani L, Montesi GF, Calamai GC, Vaccari M, Favilli S, Abbate R, Gensini GF (1997) A major involvement of the cardiovascular system in patients affected by Marfan syndrome: novel mutations in fibrillin 1 gene. J Mol Cell Cardiol 29:1877–1884CrossRefPubMed
21.
Zurück zum Zitat Tynan K, Comeau K, Pearson M, Wilgenbus P, Levitt D, Gasner C, Berg MA, Miller DC, Francke U (1993) Mutation screening of complete fibrillin-1 coding sequence: report of five new mutations, including two in 8-cysteine domains. Hum Mol Genet 2:1813–1821CrossRefPubMed Tynan K, Comeau K, Pearson M, Wilgenbus P, Levitt D, Gasner C, Berg MA, Miller DC, Francke U (1993) Mutation screening of complete fibrillin-1 coding sequence: report of five new mutations, including two in 8-cysteine domains. Hum Mol Genet 2:1813–1821CrossRefPubMed
22.
Zurück zum Zitat Takata M, Amiya E, Watanabe M, Omori K, Imai Y, Fujita D, Nishimura H, Kato M, Morota T, Nawata K, Ozeki A, Watanabe A, Kawarasaki S, Hosoya Y, Nakao T, Maemura K, Nagai R, Hirata Y, Komuro I (2014) Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome. Heart Vessels 29:478–485CrossRefPubMed Takata M, Amiya E, Watanabe M, Omori K, Imai Y, Fujita D, Nishimura H, Kato M, Morota T, Nawata K, Ozeki A, Watanabe A, Kawarasaki S, Hosoya Y, Nakao T, Maemura K, Nagai R, Hirata Y, Komuro I (2014) Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome. Heart Vessels 29:478–485CrossRefPubMed
23.
Zurück zum Zitat Grewal N, Franken R, Mulder BJ, Goumans MJ, Lindeman JH, Jongbloed MR, DeRuiter MC, Klautz RJ, Bogers AJ, Poelmann RE, Groot AC (2015) Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy? Heart Vessels. doi:10.1007/s00380-015-0703-z PubMedPubMedCentral Grewal N, Franken R, Mulder BJ, Goumans MJ, Lindeman JH, Jongbloed MR, DeRuiter MC, Klautz RJ, Bogers AJ, Poelmann RE, Groot AC (2015) Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy? Heart Vessels. doi:10.​1007/​s00380-015-0703-z PubMedPubMedCentral
24.
Zurück zum Zitat Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ (2013) Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 34:3491–3500CrossRefPubMed Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ (2013) Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 34:3491–3500CrossRefPubMed
25.
Zurück zum Zitat Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L, Pediatric Heart Network Investigators (2014) Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 371:2061–2071CrossRefPubMedPubMedCentral Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L, Pediatric Heart Network Investigators (2014) Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 371:2061–2071CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G (2015) Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 36:2160–2166CrossRefPubMed Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G (2015) Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 36:2160–2166CrossRefPubMed
Metadaten
Titel
Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24–32
verfasst von
Jun Maeda
Kenjiro Kosaki
Junko Shiono
Kazuki Kouno
Ryo Aeba
Hiroyuki Yamagishi
Publikationsdatum
21.01.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 10/2016
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0793-2

Weitere Artikel der Ausgabe 10/2016

Heart and Vessels 10/2016 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.